tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
PremiumRatingsPositive Outlook for vTv Therapeutics: Buy Rating on Cadisegliatin’s Promising Phase 3 Trial and Market Potential
2M ago
vTv Therapeutics initiated with a Buy at BTIG
Premium
The Fly
vTv Therapeutics initiated with a Buy at BTIG
2M ago
Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
Premium
Ratings
Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment
2M ago
vTv Therapeutics announces three appointments to Scientific Advisory Board
PremiumThe FlyvTv Therapeutics announces three appointments to Scientific Advisory Board
3M ago
vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders
Premium
The Fly
vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders
4M ago
vTv Therapeutics trading resumes
Premium
The Fly
vTv Therapeutics trading resumes
4M ago
Optimistic Buy Rating for vTv Therapeutics Driven by Clinical Progress and Strategic Advancements
PremiumRatingsOptimistic Buy Rating for vTv Therapeutics Driven by Clinical Progress and Strategic Advancements
5M ago
vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin
Premium
The Fly
vTv Therapeutics announces USPTO allowance of patent covering cadisegliatin
5M ago
vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial
Premium
The Fly
vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100